BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 1184740)

  • 1. Effect of insulin-glucose infusions on plasma glucagon levels in fasting diabetics and nondiabetics.
    Raskin P; Fujita Y; Unger RH
    J Clin Invest; 1975 Nov; 56(5):1132-8. PubMed ID: 1184740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of continuous physiologic hyperinsulinemia on glucose kinetics and counterregulatory hormones in normal and diabetic humans.
    Saccà L; Sherwin R; Hendler R; Felig P
    J Clin Invest; 1979 May; 63(5):849-57. PubMed ID: 447832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes.
    DeFronzo R; Deibert D; Hendler R; Felig P; Soman V
    J Clin Invest; 1979 May; 63(5):939-46. PubMed ID: 376552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia.
    Ginsberg H; Kimmerling G; Olefsky JM; Reaven GM
    J Clin Invest; 1975 Mar; 55(3):454-61. PubMed ID: 1117064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose disposal in obese non-diabetic and diabetic type II patients. A study by indirect calorimetry and euglycemic insulin clamp.
    Golay A; Defronzo RA; Thorin D; Jequier E; Felber JP
    Diabete Metab; 1988; 14(4):443-51. PubMed ID: 3066652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the suppressive effects of elevated plasma glucose and free fatty acid levels on glucagon secretion in normal and insulin-dependent diabetic subjects. Evidence for selective alpha-cell insensitivity to glucose in diabetes mellitus.
    Gerich JE; Langlois M; Noacco C; Lorenzi M; Karam JH; Korsham PH
    J Clin Invest; 1976 Aug; 58(2):320-5. PubMed ID: 783198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2 diabetic patients have increased gluconeogenic efficiency to substrate availability, but intact autoregulation of endogenous glucose production.
    Toft I; Jenssen T
    Scand J Clin Lab Invest; 2005; 65(4):307-20. PubMed ID: 16076686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of pancreatic alpha cell function in normal and diabetic subjects.
    Unger RH; Aguilar-Parada E; Müller WA; Eisentraut AM
    J Clin Invest; 1970 Apr; 49(4):837-48. PubMed ID: 4986215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral glucose and protein load on plasma glucagon and insulin concentrations in small for gestational age infants.
    Salle BL; Ruiton-Ugliengo A
    Pediatr Res; 1977 Feb; 11(2):108-12. PubMed ID: 840499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man.
    Rizza R; Verdonk C; Miles J; Service FJ; Gerich J
    J Clin Invest; 1979 Jun; 63(6):1119-23. PubMed ID: 447838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple disturbances of free fatty acid metabolism in noninsulin-dependent diabetes. Effect of oral hypoglycemic therapy.
    Taskinen MR; Bogardus C; Kennedy A; Howard BV
    J Clin Invest; 1985 Aug; 76(2):637-44. PubMed ID: 3897287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
    Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
    Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of normoglycemia during cardiac surgery.
    Carvalho G; Moore A; Qizilbash B; Lachapelle K; Schricker T
    Anesth Analg; 2004 Aug; 99(2):319-24, table of contents. PubMed ID: 15271698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of physiologic hyperglucagonemia on basal and insulin-inhibited splanchnic glucose output in normal man.
    Felig P; Wahren J; Hendler R
    J Clin Invest; 1976 Sep; 58(3):761-5. PubMed ID: 956401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperglucagonemia of renal failure.
    Bilbrey GL; Faloona GR; White MG; Knochel JP
    J Clin Invest; 1974 Mar; 53(3):841-7. PubMed ID: 4812442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of glucagon deficiency in the Houssay phenomenon of dogs.
    Nakabayashi H; Dobbs RE; Unger RH
    J Clin Invest; 1978 May; 61(5):1355-62. PubMed ID: 659597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.
    Orskov C; Jeppesen J; Madsbad S; Holst JJ
    J Clin Invest; 1991 Feb; 87(2):415-23. PubMed ID: 1991827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of insulin on the alpha-cell response to hyperglycemia in long-standing alloxan diabetes.
    Braaten JT; Faloona GR; Unger RH
    J Clin Invest; 1974 Apr; 53(4):1017-21. PubMed ID: 4592597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-Trp8-D-Cys14-somatostatin--demonstration of its differential suppressive activity in juvenile diabetics.
    Neuhaus C; Kerner W; Maier V; Pfeiffer EF
    Horm Metab Res Suppl; 1979; (8):115-8. PubMed ID: 395066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.